Where:
TBC
Surrounding areas
Massachusetts, 02114 United States
Admission:
$1399.00 - $3499.00
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/2674209-0?pid=5248
As supply issues with Ozempic persist for Novo Nordisk, and Eli Lilly launch an unconventional but affordable single-dose version of Zepbound; there has never been a more crucial time to bring the obesity and metabolic health industry together.
Join us for this inaugural event where pharmaceutical companies, biotechs, payers, and providers come together to drive innovation, foster partnerships, and enhance access to effective obesity and metabolic health treatments. With a sharp focus on GLP-1s, we will explore the business dynamics behind this ground-breaking modality and its significant impact on the health industry.
Our conference features insights from top companies and thought leaders, tackling the most pressing issues and trends in obesity and metabolic health, including:
- Transforming Obesity and Metabolic Health
- Market Access and Cost Containment
- Expanding the Therapeutic Horizons of GLP-1 Drugs
- Regulatory Challenges
Why attend?
Gain Strategic Expertise:
Deepen your understanding of regulatory and reimbursement landscapes with insights from industry leaders like Novo Nordisk, Sanofi, BCBS, and Cigna.
Access Exclusive Innovations:
Discover new indications, delivery methods, and beyond-the-pill strategies from startups and innovators, while learning what's attracting investor interest.
Unmatched Networking:
Connect with top decision-makers in obesity and cardiometabolic health, build strategic partnerships, secure investment opportunities, and advance your organization's solutions.
Don't miss your chance to be at the cutting edge of GLP-1 innovation and industry transformation.
Quote 'EVNNT10' to claim 10% off your registration.
We look forward to seeing you in Boston!
Prices:
Tier 1 - Academics / Research Institutes / Healthcare Providers / Clinicians: USD 1399.00,
Tier 2 - Start Ups (Biotech and Tech) - Pre-Series A Funding: USD 2099.00,
Tier 3 - Pharma and Biotechs / Investors / Regulators: USD 2399.00,
Tier 4 - Service Providers - Vendors and Consumer / Fitness / CDMO / CROs / Consultants / Research Tools: USD 3499.00
Speakers: Ulrik Brandt, Global Associate Director, NOVO NORDISK, Robert Gabbay Chie,f Science and Medical Officer, AMERICAN DIABETES ASSOCIATION, Soanli Malhotra, Global Development Medical Director, ASTRAZENECA, Philip Larsen, CEO, SIXPEAKS BIO, Disha Narang, Director of Obesity Medicine, ENDEAVOUR HEALTH
Saturday, Dec 07, 2024 8:30a
Crane Estate
Saturday, Dec 07, 2024 11:00a
Crystal Ballroom at Somerville Theatre
Saturday, Dec 14, 2024 12:00p
Perrin Theater, Keiter Center for the Performing Arts
Saturday, Dec 14, 2024 10:15a
Hammond Castle
Saturday, Dec 07, 2024 5:30p
John F. Kennedy Presidential Library and Museum